Tam E K, Franconi G M, Nadel J A, Caughey G H
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.
Am J Respir Cell Mol Biol. 1990 May;2(5):449-52. doi: 10.1165/ajrcmb/2.5.449.
To examine the role of endogenous proteases in limiting the bronchodilating effects of vasoactive intestinal peptide (VIP) in human airway, we studied precontracted bronchial rings from five nonsmokers undergoing heart-lung transplantation for pulmonary hypertension, either primary or secondary to congenital heart disease. The protease inhibitors aprotinin, leupeptin, phosphoramidon, and soybean trypsin inhibitors significantly potentiated the bronchodilator response to VIP. Even in the presence of the four protease inhibitors, VIP-induced bronchodilation reversed spontaneously in some tissues. These studies show that degradation by endogenous airway proteases is an important determinant of the bronchodilating potency of VIP in isolated human airway.
为研究内源性蛋白酶在限制血管活性肠肽（VIP）对人气道舒张作用中的作用，我们研究了5例因原发性或先天性心脏病继发肺动脉高压而接受心肺移植的非吸烟者的预收缩支气管环。蛋白酶抑制剂抑肽酶、亮抑肽酶、磷酰胺脒和大豆胰蛋白酶抑制剂显著增强了对VIP的支气管舒张反应。即使在存在四种蛋白酶抑制剂的情况下，VIP诱导的支气管舒张在某些组织中仍会自发逆转。这些研究表明，内源性气道蛋白酶的降解是VIP在离体人气道中舒张效力的重要决定因素。
